Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia [11]

Leukemia

Volumn 21, Issue 11, 2007, Pages 2377-2380

  Appel, I M ^a   van Kessel Bakvis, C ^a   Stigter, R ^a   Pieters, R ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; DEXAMETHASONE; PARONAL; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SUBSTITUTION; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; HYPOFIBRINOGENEMIA; LETTER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SIDE EFFECT;

EID: 35548980894     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404793     Document Type: Letter

References (4)

1. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: Effects of the disease and therapy. Thromb Res 2003; 111: 199-212.
2. van Giezen JJ, Brakkee JG, Dreteler GH, Bouma BN, Jansen JW. Dexamethasone affects platelet aggregation and fibrinolytic activity in rats at different doses which is reflected by their effect on arterial thrombosis. Blood Coagul Fibrinolysis 1994; 5: 249-255.
3. Veerman AJ, Hahlen K, Kamps WA, Van Leeuwen EF, De Vaan GA, Solbu G et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 1996; 14: 911-918.
4. Werber G. Pharmacokinetic/pharmacodynamic monitoring of L-asparaginase in children. Hematology 1995; 70 (Suppl II): 130.